XORIMAX

This brand name is authorized in Croatia, Ecuador, Estonia, Hong Kong SAR China, Lithuania, Poland, Singapore.

Active ingredients

The drug XORIMAX contains one active pharmaceutical ingredient (API):

1	Cefuroxime UNII Z49QDT0J8Z - CEFUROXIME AXETIL
	Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
	Read more about Cefuroxime

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DC02	Cefuroxime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins
Discover more medicines within J01DC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29403-10-10, 29657-02-11
EE	Ravimiamet	1219755, 1219766, 1219777, 1219788, 1219799, 1219801, 1219812, 1219823, 1624801
HK	Department of Health Drug Office	58622, 58709
HR	Agencija za lijekove i medicinske proizvode	HR-H-230586705, HR-H-684676442
LT	Valstybinė vaistų kontrolės tarnyba	1004311, 1017583, 1017584, 1017585, 1022056, 1022057, 1052441, 1052443, 1069688, 1081774, 1081775
PL	Rejestru Produktów Leczniczych	100139841, 100140465, 100335401, 100342170, 100365891
SG	Health Sciences Authority	13287P